Blueprint Medicines Corporation (BPMC) earnings
BPMC earnings moved a median of -0.12% by the close. Quarterly and annual BPMC reports and results, each read against the price at its own news timestamp. Back to the BPMC overview →
16 measured BPMC earnings events.
Where these BPMC earnings landedvs 16 measured BPMC earnings reactions
| Middle 50% of BPMC earnings reactions | -2.40% to +3.10% |
|---|---|
| Median reaction (to close) | -0.12% |
| Measured reactions | 16 |
Point-in-time · zero look-ahead
Half of the 16 BPMC earnings events with a measured close landed between -2.40% and +3.10%; 44% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance | Press release | +0.80% | +8.90% | |
| Form 10-Q Blueprint Medicines Corp For: Mar 31 | SEC filing · Form 10-Q | +0.95% | +5.43% | |
| Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | Press release | -0.35% | +3.40% | |
| Form 10-K Blueprint Medicines Corp For: Dec 31 | SEC filing · Form 10-K | -0.65% | -2.43% | |
| Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance | Press release | +1.52% | -3.00% | |
| Form 10-Q Blueprint Medicines Corp For: Sep 30 | SEC filing · Form 10-Q | -1.60% | -1.93% | |
| Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 | Press release | +0.00% | -0.82% | |
| Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance | Press release | +0.27% | -5.84% | |
| Form 10-Q Blueprint Medicines Corp For: Jun 30 | SEC filing · Form 10-Q | -0.21% | +0.35% | |
| Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 | Press release | -0.70% | -0.01% | |
| Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance | Press release | -0.88% | +3.00% | |
| Form 10-Q Blueprint Medicines Corp For: Mar 31 | SEC filing · Form 10-Q | -0.97% | -2.40% | |
| Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 | Press release | -0.45% | +1.10% | |
| Form 10-K Blueprint Medicines Corp For: Dec 31 | SEC filing · Form 10-K | +2.30% | -0.22% | |
| Blueprint Medicines Reports Third Quarter 2023 Results | Press release | +5.21% | +13.90% | |
| Form 10-Q Blueprint Medicines Corp For: Sep 30 | SEC filing · Form 10-Q | -2.16% | -4.64% |
Keep exploring
More BPMC: analyst actions → · SEC filings → · BPMC overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SPRING BANK PHARMACEUTICALS (SBPH) | 404 | 0.00% | 37% |
| AKCEA THERAPEUTICS (AKCA) | 401 | 0.00% | 49% |
| EDGE THERAPEUTICS (EDGE) | 401 | -0.05% | 41% |
| Esperion Therapeutics, Inc. (ESPR) | 401 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.